Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
Høilund-Carlsen PF, Alavi A, Barrio JR, Castellani RJ, Costa T, Herrup K, Kepp KP, Neve RL, Perry G, Revheim ME, Robakis NK, Sensi SL, Vissel B.
Høilund-Carlsen PF, et al. Among authors: sensi sl.
Ageing Res Rev. 2024 Aug;99:102348. doi: 10.1016/j.arr.2024.102348. Epub 2024 Jun 1.
Ageing Res Rev. 2024.
PMID: 38830549
Review.